知镜 Cognispect · 医学文献与研究工作台

Clinical implications of germline and somatic genetic testing in ovarian carcinoma: BRCA and beyond. The PERSONA-Ovary trial.

Betella I, Bonetti E, Ribero L, Zanzottera C, Fumagalli C, Sangalli C, Garbi A, Montinaro A, Multinu F, Marino E, Bonizzi G, Molin MD, Belloni E, Capra M, Kahler-Ribeiro-Fontana S, Rioldi E, Saraca A, Feroce I, Sbriglia A, Vacirca D, Sala I, Bagnardi V, Peruzzotti G, Fusco N, Peccatori F, Galimberti V, Guerini Rocco E, Bonanni B, Colombo N, Mazzarella L.
Gynecologic oncology · 2026-10-16 · PMID 42887399

文献摘要

Objective The PERSONA-Ovary study evaluated germline pathogenic/likely-pathogenic variant prevalence, feasibility of unselected multigene testing integration in routine clinical care, and germline-somatic BRCA concordance in ovarian cancer patients. Methods We conducted a prospective observational study of consecutive ovarian carcinoma patients treated at a tertiary-cancer care center, between July 2018 and September 2021. Germline multigene panel testing was performed using next-generation sequencing. Feasibility was assessed by informative rate and turnaround time. Germline-somatic concordance was assessed in patients with paired tumor BRCA results. Results Among 320 patients, pathogenic/likely-pathogenic variants were identified in 95 (29.7%, 95% CI 24.7-35.0); 81 (85.3%, 95% CI 76.5-91.7) carried mutations in ovarian cancer susceptibility genes, including 60 with BRCA alterations (63.2%, BRCA1 n=43, BRCA2 n=17). Germline testing was informative in all patients (100%). Median turnaround time was 221days (IQR 173-284), improving significantly across study periods (p Conclusion Unselected germline multigene panel testing was technically feasible and clinically informative in routine ovarian cancer care. Pathogenic/likely-pathogenic variants were identified in 29.7% of patients, supporting germline testing integration into contemporary ovarian cancer management. Although germline-first strategies maximize hereditary cancer detection, dedicated molecular workflows remain necessary to ensure clinically actionable turnaround times.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。